SUPERNUS PHARMACEUTICALS, INC. 4

SVP & Chief Tech. Ops. Officer Frank Mottola received 1,650 shares of Supernus Pharmaceuticals common stock through the vesting of Performance Share Units.

On July 29, 2026, Frank Mottola, SVP and Chief Technical Operations Officer of Supernus Pharmaceuticals, Inc., acquired 1,650 shares of common stock as a result of the vesting of previously granted Performance Share Units, which were awarded on February 19, 2025 and partially vested upon the achievement of individual performance objectives set on May 3, 2025; this award increased his direct ownership to 1,650 shares, with no transaction price disclosed.

Filing Facts

CIK

1356576

Ticker

SUPN

Form

4

Source Type

fda

Accession

0001804567-26-000012

Alert Tier

4